Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Wave Life Sciences Ltd.
Headquarters: Cambridge, MA, United States of America
Website: http://wavelifesciences.com
Year Founded: 2012
Status: Public
Industry Sector: HealthTechnology
CEO: Paul B. Bolno, MD, MBA
Number Of Employees: 288
Enterprise Value: $1,441,692,279
PE Ratio: -7.59
Exchange/Ticker 1: NASDAQ:WVE
Exchange/Ticker 2: N/A
Latest Market Cap: $1,019,146,944
BioCentury | Apr 2, 2025
Product Development
VEGF bispecifics make inroads in other cancers, and more: Clinical Report
Plus: The week’s gainers and decliners after data
BioCentury | Jan 22, 2025
Finance
2025 Biotech Preview: Markets, Catalysts and AI
Assessing the bull and bear arguments and the catalysts for biotech in the New Year
BioCentury | Jan 18, 2025
Product Development
2025 catalysts: New mechanisms in obesity, neurology, ophthalmology
New Year to put new obesity targets to the test, as all eyes on semaglutide in Alzheimer’s and launches in schizophrenia, AMD
BioCentury | Dec 30, 2024
Product Development
The uncertainty principle: Hello, 2025
BioCentury’s analysts look back at a year when innovation was hot, but markets were not, and predict what’ll make news in 2025
BioCentury | Oct 22, 2024
Finance
Venture funds, a new chapter for MS & Wave’s data: a BioCentury podcast
What Forbion’s $2.2B raise says about the state of venture, NIH’s Daniel Reich on MS and RNA-editing oligo data from Wave
BioCentury | Oct 22, 2024
Deals
Pfizer deepens degrader footprint, Novartis taps China’s Baiyu, and more
Deals report: Pfizer-Triana to discover molecular glues; Novartis taps Baiyu for cancer small molecule; plus Ocean-Molecure, Takeda-Wave and more
BioCentury | Oct 17, 2024
Product Development
Wave data propel RNA-editing stocks, but are all platforms created equal?
In first human RNA-editing data, Wave reports positive results from WVE-006 in alpha-1 antitrypsin deficiency
BioCentury | Oct 1, 2024
Product Development
Schizophrenia and sickle cell drugs, D.C. update: a BioCentury podcast
A first-in-class approval for BMS. A Pfizer withdrawal. ODAC & PD-L1. Congress’ unfinished business. BioAge’s NASDAQ IPO
BioCentury | Sep 27, 2024
Finance
Wave financing, BioAge IPO help biotech end September strong
In BioCentury’s latest Public Equity Report, Wave raises $200M on standout DMD data and BioAge marks fourth NASDAQ IPO this month
BioCentury | Sep 25, 2024
Product Development
Wave claims early lead in second-generation exon 53 skipping
In BioCentury’s latest Clinical Report, Wave gains on DMD data, plus updates from Daiichi and AZ, Black Diamond, Metsera, Biohaven and more
Items per page:
1 - 10 of 82